Chimeric antibodies for treatment of amyloid deposition diseases

Patent metadata

Field	Value
Publication number	US-11530257-B2
Application number	US-201816626613-A
Country	US
Kind code	B2
Filing date	Jun 28, 2018
Priority date	Jun 29, 2017
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

A chimeric mouse-human antibody for treatment of amyloid deposition diseases, pharmaceutical compositions comprising the antibody, methods and materials for producing the antibody, and methods for treating an amyloid deposition disease using the antibody and the pharmaceutical composition.

First claim

What is claimed is:

1. A chimeric mouse-human antibody for treating primary amyloidosis comprising a VK and VH region, wherein the VK region is SEQ ID NO: 47 and the VH region is SEQ ID NO: 48, wherein the chimeric antibody binds to amyloid fibrils with a higher affinity than its murine equivalent.

2. The chimeric mouse-human antibody of claim 1 which binds to an epitope expressed by the β-pleated sheet configuration of amyloid fibrils with higher affinity than the mouse antibody comprising the VK region of SEQ ID NO: 36 and the VH region of SEQ ID NO: 35.

3. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

4. A method of treating an amyloid deposition disease in a human patient in need of such treatment which comprises administering to the patient the antibody of claim 1 together with a pharmaceutically acceptable carrier, in an amount effective to treat said amyloid deposition disease.

5. The method of claim 4 wherein the amyloid deposition disease is primary amyloidosis.

6. A method of detecting the presence of amyloid deposits in a patient suspected of having such deposits which comprises administering to the patient an amount of the antibody of claim 1 having a detectable label attached thereto, the amount of antibody administered being sufficient to allow detection of amyloid deposits if such are present.

7. The method of claim 6 wherein the detectable label is 1241.

8. A polypeptide selected from SEQ. ID NO: 47 and SEQ. ID NO: 48.

Assignees

• Univ Columbia

Inventors

• Jones Tarran
• Levy Alison
• O'Brien Siobhan

Classifications

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K16/46

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title